Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
08/02/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
04/21/2022 | 1959.73% | Oppenheimer | $5 → $6 | Maintains | Outperform |
02/23/2021 | 1788.09% | HC Wainwright & Co. | $10 → $5.5 | Maintains | Buy |
07/07/2020 | 2989.6% | HC Wainwright & Co. | $8 → $9 | Maintains | Buy |
06/16/2020 | 2989.6% | Cantor Fitzgerald | $3 → $9 | Maintains | Overweight |
12/24/2019 | 2646.31% | Oppenheimer | → $8 | Initiates Coverage On | → Outperform |
08/29/2019 | 2646.31% | HC Wainwright & Co. | → $8 | Initiates Coverage On | → Buy |
11/15/2018 | 2989.6% | Cantor Fitzgerald | → $9 | Initiates Coverage On | → Overweight |
03/19/2018 | — | JP Morgan | Downgrades | Neutral → Underweight | |
08/30/2017 | — | JP Morgan | Downgrades | Overweight → Neutral | |
08/15/2017 | — | JP Morgan | Upgrades | Neutral → Overweight |
Otonomy Questions & Answers
The latest price target for Otonomy (NASDAQ: OTIC) was reported by HC Wainwright & Co. on August 2, 2022. The analyst firm set a price target for $0.00 expecting OTIC to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for Otonomy (NASDAQ: OTIC) was provided by HC Wainwright & Co., and Otonomy downgraded their neutral rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Otonomy, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Otonomy was filed on August 2, 2022 so you should expect the next rating to be made available sometime around August 2, 2023.
While ratings are subjective and will change, the latest Otonomy (OTIC) rating was a downgraded with a price target of $0.00 to $0.00. The current price Otonomy (OTIC) is trading at is $0.29, which is out of the analyst's predicted range.